Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.

The recombinant human fusion protein L19TNFα was created with the intention to target TNFα directly to tumor tissues with the result in high and sustained intralesional bioactive TNFα concentrations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intratumoral Administration of L19IL2/L19TNF

NCT02076633

Malignant Melanoma, Skin

COMPLETED PHASE2

Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment

NCT01920516

Metastatic Melanoma

UNKNOWN

L19TNFα in Patients With Advanced Solid Tumors

NCT01253837

Solid Tumors Colorectal Cancer

COMPLETED PHASE1/PHASE2

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

NCT00001296

Melanoma

COMPLETED PHASE3

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

NCT04812470

Metastatic Uveal Melanoma Metastatic Cutaneous Melanoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Intransit Stage III/IV Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

L19TNFα plus melphalan

Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).

Group Type EXPERIMENTAL

Isolated inferior limb perfusion

Intervention Type OTHER

Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isolated inferior limb perfusion

Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects aged \>18 years.
2. Histologically or cytologically confirmed intransit stage III/IV melanoma of lower extremity distal to the apex of the femoral triangle
3. ECOG performance status ≤ 2.
4. Subjects must have at least one unidimensional clinically measurable lesion as defined by RECIST criteria (see Section 8). This lesion must not have been irradiated within four weeks during previous treatments.
5. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and haemoglobin (Hb) ≥ 9.5 g/dl.
6. All acute adverse effects (excluding alopecia) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have been resolved to ≤ Grade 1, except elevated liver transaminases judged to be associated with tumor infiltration (see below) (graded according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events, version 3.0 \[CTCAE, v.3.0\].
7. Alkaline phosphatase (AP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 2.0 mg/dL unless liver involvement by the tumor, in which case the transaminase levels up to 5 x ULN are allowed.
8. Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 60 mL/min.
9. Testing negative for acute or chronic infection with hepatitis B or C virus, or human immunodeficiency virus 1 or 2.
10. Negative pregnancy test for females of childbearing potential at the screening visit.
11. Commitment from subject to practice medically appropriate/acceptable method of birth control (e.g., hormonal, condoms or other adequate barrier controls, intrauterine contraceptive device, or sterilization) beginning at the screening visit and continuing until 3 months following the treatment with study drug
12. Able to provide written Informed Consent
13. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria

1. Breastfeeding women
2. Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the Investigator, would place the subject at undue risk or interfere with the study.
3. Active autoimmune disease.
4. Cardiac disease as manifested by any of the following:

* \> Grade II heart failure, graded per New York Heart Association (NYHA) criteria.
* Unstable angina pectoris
* Acute or subacute coronary syndromes, including myocardial infarction, occurring with 1 year prior to study treatment
* Arrhythmia needing continuous treatment
* Ejection fraction less than the institutional lower limit of normal as assessed by multigated radionuclide angiography (MUGA) scan or echocardiogram
5. Uncontrolled hypertension.
6. History of claudication or Ischemic peripheral vascular disease (Grade IIb-IV).
7. Chronic obstructive pulmonary disease or other chronic pulmonary disease with PFTs less than 50% predicted for age.
8. Symptomatic cerebrovascular disease.
9. Active peptic ulcer disease.
10. Concurrent infection of HIV.
11. Severe diabetic retinopathy.
12. Major surgery or trauma within 4 weeks prior to start of study treatment.
13. Hypersensitivity to melphalan or TNFα or other intravenously administered human proteins/peptides/antibodies.
14. Chemotherapy, radiation therapy or therapy with an investigational agent within 4 weeks prior to start of study treatment.
15. Any regional therapy to the affected extremity within 2 months prior to start of study treatment.
16. Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.
17. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
18. Subject requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
19. Participation in another interventional clinical trial during participation in this trial.
20. Any conditions that in the opinion of the Investigator could hamper compliance with the study protocol.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No